REDWOOD CITY, Calif., May 27, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences (CHRS), Inc. , today announced a clinical collaboration with STORM Therapeutics, Ltd. (“STORM”) to evaluate STC-15, a METTL3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results